Peer-reviewedCC BY-NC-ND 4.0BMC Medicine
Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study
Related
- Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
- Adjuvant Therapy in Resected Adrenocortical Carcinoma: Current Evidence and Patient Selection
- Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
- Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
- Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
BibTeX
@article{yu2026adjuvant,
title = {{Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study}},
author = {Juemin Yu and Jialiang Wen and Tao Chen and Xinchen Shen and Long Xu and Mengmeng Zhao and Jiajun Deng and Junqi Wu and Deping Zhao and Yunlang She and Chang Chen},
journal = {BMC Medicine},
year = {2026},
month = oct,
doi = {10.1186/s12916-026-05336-3},
url = {https://link.springer.com/article/10.1186/s12916-026-05336-3},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study
AU - Juemin Yu
AU - Jialiang Wen
AU - Tao Chen
AU - Xinchen Shen
AU - Long Xu
AU - Mengmeng Zhao
AU - Jiajun Deng
AU - Junqi Wu
AU - Deping Zhao
AU - Yunlang She
AU - Chang Chen
PY - 2026
DA - 2026/10/21
JO - BMC Medicine
DO - 10.1186/s12916-026-05336-3
UR - https://link.springer.com/article/10.1186/s12916-026-05336-3
SN - 1741-7015
ER -